#niraparib
#niraparib
[ follow ]
#pancreatic-cancer #clinical-trials #breast-cancer #immunotherapy #cancer-treatment #cancer-research
from24/7 Wall St.
2 weeks ago5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up
Incyte tops this list due to its rare combination of commercial scale, cash generation, and pipeline depth. The company posted FY2025 revenue of $5.14 billion, up 21.2% YoY, anchored by Jakafi generating $828.2 million in Q4 2025 alone (+7% YoY) and Opzelura delivering $207.3 million (+28% YoY). With $3.58 billion in cash and 14 pivotal clinical trials underway, Incyte offers an acquirer immediate revenue, margin expansion potential, and a deep oncology pipeline spanning KRASG12D, CDK2 inhibition, and mutCALR.
Venture
fromwww.theguardian.com
1 week agoRepurposed drug may extend survival in aggressive ovarian cancer, trial shows
The study published in the Lancet analyzed data from 381 patients with platinum-resistant ovarian cancer, revealing a 35% reduction in the risk of death among those treated with relacorilant compared to usual care.
Cancer
London startup
fromBusiness Matters
1 month agoBIOCAPTIVA raises 1.58m to transform liquid biopsy sample preparation
BIOCAPTIVA secured £1.58 million funding to commercialize msX technology, which simplifies blood sample preparation for cancer diagnostics by using magnetic bead extraction to isolate cell-free DNA directly from whole blood.
Medicine
fromBusiness Matters
1 month agoFlavia Pichiorri: Turning Cancer Research Into Real Therapies
Dr. Flavia Pichiorri bridges laboratory discoveries and clinical applications in blood cancer research, focusing on therapeutic targets and radiation strategies to accelerate patient treatment outcomes.
OMG science
fromHarvard Gazette
2 months agoWhy did that cancer cell become drug-resistant? - Harvard Gazette
TimeVault records and stores cellular gene-expression history inside living cells, enabling retrieval of past gene-activity information to study differentiation, stress responses, adaptation, and drug resistance.
Coronavirus
fromwww.npr.org
1 month agoIvermectin is making a post-pandemic comeback, among cancer patients
Ivermectin, effective for parasitic infections in animals and humans, is being promoted as a cure-all despite lack of evidence for COVID-19 and cancer treatment, prompting five states to allow over-the-counter access.
fromwww.nature.com
2 months agoAuthor Correction: The genomic landscape of response to EGFR blockade in colorectal cancer
In Extended Data Fig. 8 of this article, a micrograph shown in the left column (panel AZD) was inadvertently duplicated during figure preparation. The intended image was meant to show phospho-ERK (P-ERK) levels in a MAP2K1-mutant patient-derived xenograft (PDX) exposed to the MEK inhibitor AZD6244 (AZD). However, this image was accidentally overlaid with a micrograph from Extended Data Fig. 10 (left column, panel PAN), which displays P-ERK levels in an EGFR-mutant PDX exposed to panitumumab (PAN).
Cancer
fromBusiness Insider
1 month agoStop ignoring subtle signs of cancer. A doctor explains when to get medical help.
Early cancer symptoms are often subtle and easily missed, including unexplained fatigue, persistent pain, and digestive changes; persistent symptoms lasting over a week warrant medical evaluation.
fromHarvard Gazette
2 months agoAmericans living longer after cancer diagnosis - Harvard Gazette
New findings on cancer survival rates offer hope for the more than 2 million Americans diagnosed each year. Seven out of 10 Americans diagnosed with cancer now survive five years or more, according to the American Cancer Society, a 7 percent increase since the mid-1990s, when the rate stood at 63 percent. The survival rate data - from patients diagnosed with cancer between 2015 and 2021 - showed, significantly, that those with high-mortality cancers and advanced diagnoses had the largest gains.
Public health
Medicine
fromSilicon Canals
2 months agoEurope Oncology Genomics Tracker Captures Oncologist Perspectives Across Major European Markets - Data Report by DeciBio Consulting LLC - Silicon Canals
Genomic testing adoption for solid tumor oncology is growing across EU-5 with varied country-specific drivers and infrastructure tracked via a survey of 100+ oncologists.
fromBrooklyn Eagle
2 months agoDr. Anirban Maitra brings extensive GI oncology leadership as new director of Perlmutter Cancer Center
CITYWIDE - NYU LANGONE HEALTH HAS APPOINTED DR. ANIRBAN MAITRA, a leader in gastrointestinal oncology, as the new director of its Laura and Isaac Perlmutter Cancer Center, an NCI-designated Comprehensive Cancer Center. Dr. Maitra is a preeminent physician-scientist whose work has widely influenced the field of pancreatic cancer research. As the inaugural scientific director of the Pancreatic Cancer Research Center at the University of Texas MD Anderson Cancer Center in Houston, Dr. Maitra focused his work on early detection and biomarker development, considered two key avenues for effective cancer treatments.
Medicine
Cancer
fromenglish.elpais.com
1 month agoThree sisters and a dilemma: what to do when you inherit a genetic mutation that can cause cancer
Three sisters discovered they carry the BRCA1 gene mutation, which significantly increases breast and ovarian cancer risk, after their cousin's rapid cancer diagnosis prompted family genetic testing.
[ Load more ]